{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:53:06Z","timestamp":1790679186732,"version":"4.1.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T00:00:00Z","timestamp":1421971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"University Hospital Foundation of the University of Alberta"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Anderson\u2013Fabry disease (AFD) is an important X-linked metabolic disease resulting in progressive end-organ involvement, with cardiac disease being the dominant determinant of survival in a gender-dependent manner. Recent epidemiological screening for AFD suggests the prevalence is much higher than previously recognized, with estimates of 1:3000. Our aim was to discover novel plasma biomarker signatures in adult patients with AFD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We used an unbiased proteomic screening approach to discover novel plasma biomarker signatures. In the discovery cohort of 46 subjects, 14 healthy controls and 32 patients with AFD, we used a mass spectrometry iTRAQ proteomic approach followed by multiple reaction monitoring (MRM) assays to identify biomarkers. Of the 38 protein groups discovered by iTRAQ, 18 already had existing MRM assays. Based on MRM, we identified an eight-protein biomarker panel (22 kDa protein, afamin, \u03b11 antichymotrypsin, apolipoprotein E, \u03b2-Ala His dipeptidase, haemoglobin \u03b1-2, isoform 1 of sex hormone-binding globulin, and peroxiredoxin 2) that was very specific and sensitive for male AFD patients. In female AFD patients, we identified a nine-marker panel of proteins with only three proteins, apolipoprotein E, haemoglobin \u03b1-2, and peroxiredoxin 2, common to both genders, suggesting a gender-specific alteration in plasma biomarkers in patients with AFD. The biomarkers were validated in plasma samples from 48 subjects using MRM, and they performed inferiorly in patients with heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We have identified gender-specific plasma protein biomarker panels that are specific and sensitive for the AFD phenotype. The gender-specific panels offer important insight into potential differences in pathophysiology and prognosis between males and females with AFD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ejhf.230","type":"journal-article","created":{"date-parts":[[2015,1,23]],"date-time":"2015-01-23T21:50:21Z","timestamp":1422049821000},"page":"291-300","source":"Crossref","is-referenced-by-count":46,"title":["Gender-Specific Plasma Proteomic Biomarkers in Patients with Anderson\u2013Fabry disease"],"prefix":"10.1093","volume":"17","author":[{"given":"Zsuzsanna","family":"Hollander","sequence":"first","affiliation":[{"name":"Centre of Excellence for Prevention of Organ Failure (PROOF Centre) , Vancouver ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darlene L.Y.","family":"Dai","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Prevention of Organ Failure (PROOF Centre) , Vancouver ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan N.","family":"Putko","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haran","family":"Yogasundaram","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet E.","family":"Wilson-McManus","sequence":"additional","affiliation":[{"name":"Centre of Excellence for Prevention of Organ Failure (PROOF Centre) , Vancouver ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard B.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Alberta , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneal","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics and Pediatrics, University of Calgary , Calgary ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"West","sequence":"additional","affiliation":[{"name":"Department of Medicine, Dalhousie University , Halifax ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"McManus","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of British Columbia (UBC) , Vancouver ,","place":["Canada"]},{"name":"UBC James Hogg Research Centre , Vancouver ,","place":["Canada"]},{"name":"Institute for Heart\u2009+\u2009Lung Health , Vancouver ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin Y.","family":"Oudit","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , Edmonton ,","place":["Canada"]},{"name":"Mazankowski Alberta Heart Institute , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,1,23]]},"reference":[{"key":"2026011921083993600_ejhf230-bib-0001","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-146-6-200703200-00007","article-title":"Narrative review: Fabry disease","volume":"146","author":"Clarke","year":"2007","journal-title":"Ann Intern Med"},{"key":"2026011921083993600_ejhf230-bib-0002","article-title":"Anderson\u2013Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment","author":"Putko","year":"2014","journal-title":"Heart Fail Rev"},{"key":"2026011921083993600_ejhf230-bib-0003","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"2026011921083993600_ejhf230-bib-0004","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCGENETICS.109.862920","article-title":"High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population","volume":"2","author":"Lin","year":"2009","journal-title":"Circ Cardiovasc Genet"},{"key":"2026011921083993600_ejhf230-bib-0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","article-title":"Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria","volume":"379","author":"Mechtler","year":"2012","journal-title":"Lancet"},{"key":"2026011921083993600_ejhf230-bib-0006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/jhg.2013.48","article-title":"Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot study","volume":"58","author":"Inoue","year":"2013","journal-title":"J Hum Genet"},{"key":"2026011921083993600_ejhf230-bib-0007","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMcps1209279","article-title":"Clinical problem-solving. In the thick of it","volume":"368","author":"Rao","year":"2013","journal-title":"N Engl J Med"},{"key":"2026011921083993600_ejhf230-bib-0008","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson\u2013Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"2026011921083993600_ejhf230-bib-0009","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS\u2014Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"2026011921083993600_ejhf230-bib-0010","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ejheart.2008.01.016","article-title":"Oxidized proteins in plasma of patients with heart failure: role in endothelial damage","volume":"10","author":"Banfi","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"2026011921083993600_ejhf230-bib-0011","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026011921083993600_ejhf230-bib-0012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCGENETICS.110.957811","article-title":"Targeting proteases in cardiovascular diseases by mass spectrometry-based proteomics","volume":"5","author":"Klingler","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"2026011921083993600_ejhf230-bib-0013","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/ejhf.65","article-title":"NCE CECR PROOF Prevention of Organ Failure (PROOF) Centre of Excellence. Proteomic biomarkers of recovered heart function","volume":"16","author":"Hollander","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026011921083993600_ejhf230-bib-0014","first-page":"157","article-title":"Fabry\u2019s disease: enzymatic diagnosis of hemizygotes and heterozygotes. Alpha-galactosidase activities in plasma, serum, urine, and leukocytes","volume":"81","author":"Desnick","year":"1973","journal-title":"J Lab Clin Med"},{"key":"2026011921083993600_ejhf230-bib-0015","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/eurjhf\/hfq080","article-title":"Screening for Fabry disease using genetic testing","volume":"12","author":"Weidemann","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921083993600_ejhf230-bib-0016","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/eurjhf\/hfq073","article-title":"Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women","volume":"12","author":"Havndrup","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"2026011921083993600_ejhf230-bib-0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCGENETICS.113.000249","article-title":"Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease","volume":"7","author":"Niemann","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"2026011921083993600_ejhf230-bib-0018","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"T1 mapping with cardiovascular MRI is highly sensitive for fabry disease independent of hypertrophy and sex","volume":"6","author":"Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026011921083993600_ejhf230-bib-0019","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.echo.2013.09.005","article-title":"Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements","volume":"26","author":"Shanks","year":"2013","journal-title":"J Am Soc Echocardiogr"},{"key":"2026011921083993600_ejhf230-bib-0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/j.1399-0004.2004.00219.x","article-title":"The Mainz Severity Score Index: a new instrument for quantifying the Anderson\u2013Fabry disease phenotype, and the response of patients to enzyme replacement therapy","volume":"65","author":"Whybra","year":"2004","journal-title":"Clin Genet"},{"key":"2026011921083993600_ejhf230-bib-0021","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1681\/ASN.2007020199","article-title":"Evaluation of the modification of diet in renal disease study equation in a large diverse population","volume":"18","author":"Stevens","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026011921083993600_ejhf230-bib-0022","volume-title":"Canadian Faby Disease Treatment Guidelines 2012","author":"West"},{"key":"2026011921083993600_ejhf230-bib-0023","doi-asserted-by":"crossref","first-page":"e1002963","DOI":"10.1371\/journal.pcbi.1002963","article-title":"Biomarkers in Transplantation and the NCE CECR Prevention of Organ Failure Centre of Excellence Teams. Computational biomarker pipeline from discovery to clinical implementation: plasma proteomic biomarkers for cardiac transplantation","volume":"9","author":"Cohen Freue","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"2026011921083993600_ejhf230-bib-0024","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nbt.1546","article-title":"Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma","volume":"27","author":"Addona","year":"2009","journal-title":"Nat Biotechnol"},{"key":"2026011921083993600_ejhf230-bib-0025","doi-asserted-by":"crossref","DOI":"10.2202\/1544-6115.1027","article-title":"Linear models and empirical bayes methods for assessing differential expression in microarray experiments","volume":"3","author":"Smyth","year":"2004","journal-title":"Stat Appl Genet Mol Biol"},{"key":"2026011921083993600_ejhf230-bib-0026","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1056\/NEJM199508033330504","article-title":"An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy","volume":"333","author":"Nakao","year":"1995","journal-title":"N Engl J Med"},{"key":"2026011921083993600_ejhf230-bib-0027","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.CIR.0000012626.81324.38","article-title":"Prevalence of Anderson\u2013Fabry disease in male patients with late onset hypertrophic cardiomyopathy","volume":"105","author":"Sachdev","year":"2002","journal-title":"Circulation"},{"key":"2026011921083993600_ejhf230-bib-0028","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/01.CIR.0000139847.74101.03","article-title":"Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy","volume":"110","author":"Chimenti","year":"2004","journal-title":"Circulation"},{"key":"2026011921083993600_ejhf230-bib-0029","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson\u2013Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson\u2013Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"2026011921083993600_ejhf230-bib-0030","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A\u2014replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"2026011921083993600_ejhf230-bib-0031","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.jacc.2013.08.1644","article-title":"The MOGE(S) classification for a phenotype\u2013genotype nomenclature of cardiomyopathy: endorsed by the World Heart Federation","volume":"62","author":"Arbustini","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2026011921083993600_ejhf230-bib-0032","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"2026011921083993600_ejhf230-bib-0033","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1161\/01.CIR.0000091253.71282.04","article-title":"Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study","volume":"108","author":"Weidemann","year":"2003","journal-title":"Circulation"},{"key":"2026011921083993600_ejhf230-bib-0034","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"2026011921083993600_ejhf230-bib-0035","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/eurheartj\/ehi143","article-title":"The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease","volume":"26","author":"Weidemann","year":"2005","journal-title":"Eur Heart J"},{"key":"2026011921083993600_ejhf230-bib-0036","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026011921083993600_ejhf230-bib-0037","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/jmg.38.11.769","article-title":"Anderson\u2013Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females","volume":"38","author":"MacDermot","year":"2001","journal-title":"J Med Genet"},{"key":"2026011921083993600_ejhf230-bib-0038","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet Med"},{"key":"2026011921083993600_ejhf230-bib-0039","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ymgme.2011.05.008","article-title":"Diagnostic dilemma: a young woman with Fabry disease symptoms, no family history, and a \u2018sequencing cryptic\u2019 alpha-galactosidase A large deletion","volume":"104","author":"Feldt-Rasmussen","year":"2011","journal-title":"Mol Genet Metab"},{"key":"2026011921083993600_ejhf230-bib-0040","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1523-1755.2005.00294.x","article-title":"Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey","volume":"67","author":"Kleinert","year":"2005","journal-title":"Kidney Int"},{"key":"2026011921083993600_ejhf230-bib-0041","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026011921083993600_ejhf230-bib-0042","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.2174\/092986712800784739","article-title":"Novel gb(3) isoforms detected in urine of fabry disease patients: a metabolomic study","volume":"19","author":"Auray-Blais","year":"2012","journal-title":"Curr Med Chem"},{"key":"2026011921083993600_ejhf230-bib-0043","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol Genet Metab"},{"key":"2026011921083993600_ejhf230-bib-0044","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ymgme.2012.07.003","article-title":"Mutant alpha-galactosidase A with M296I does not cause elevation of the plasma globotriaosylsphingosine level","volume":"107","author":"Mitobe","year":"2012","journal-title":"Mol Genet Metab"},{"key":"2026011921083993600_ejhf230-bib-0045","doi-asserted-by":"crossref","first-page":"360","DOI":"10.2215\/CJN.06090809","article-title":"Biomarkers of Fabry disease nephropathy","volume":"5","author":"Schiffmann","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026011921083993600_ejhf230-bib-0046","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1039\/c3mb25402j","article-title":"Alteration of proteomic profiles in PBMC isolated from patients with Fabry disease: preliminary findings","volume":"9","author":"Cigna","year":"2013","journal-title":"Mol Biosyst"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fejhf.230","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/3\/291\/66423508\/eurjhf_17_3_291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/17\/3\/291\/66423508\/eurjhf_17_3_291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:08:52Z","timestamp":1768874932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/17\/3\/291\/8426601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1,23]]},"references-count":46,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,1,23]]},"published-print":{"date-parts":[[2015,3,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.230","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,3]]},"published":{"date-parts":[[2015,1,23]]}}}